# GRoningen Early-PD Ambroxol Treatment

> **NCT05830396** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University Medical Center Groningen** · enrollment: 80 (estimated)

## Conditions studied

- Parkinson
- Parkinson Disease

## Interventions

- **DRUG:** Ambroxol Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05830396
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05830396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05830396, "GRoningen Early-PD Ambroxol Treatment". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05830396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*